Developer docs
API playgroundTry for free, no card

Search company profiles

BioSpectra

Full company profile

uuid000eipy

Namestring
BioSpectra
Legal namestring
BioSpectra, Inc.
Websiteurl
biospectra.us
Company typeenum
Private
Founded yearint
1995
Descriptiontext

BioSpectra, Inc. is a privately-owned, US-domiciled (Pennsylvania) manufacturer of bulk cGMP fine chemicals, biological buffers, pharmaceutical excipients, functional carbohydrates, and APIs, with operations since 1995 across approximately 370,000 square feet of GMP-licensed space in five facilities in Pennsylvania and Ontario. Its core product categories are cGMP Fine Chemicals (process chemicals, chlorinated amino acids, large-volume solutions such as NaOH and guanidine HCl), cGMP Biological Buffers (HEPES, MES, MOPS, Tris, Bis-Tris and related zwitterionic buffers in biotech, excipient, LBLE, and ultra-low-endotoxin grades), Functional and Compendial Excipients (carbohydrates including D-Galactose, Trehalose and Dextran; parenteral-grade excipients), cGMP APIs (e.g., Potassium Bromide, Tromethamine/Tris), and Custom Manufacturing Services including spray-dry processing. Manufacturing runs under FDA registration, ICH Q7 for APIs, and IPEC GMP for excipients, with additional EU REACH registrations across multiple products and CEP/CPP country authorizations; product quality tiers include ICH Q7 GMP, IPEC GMP, and ISO registered QMS grades.

The company sells exclusively to enterprise pharmaceutical and biopharmaceutical buyers — leading bio-pharma companies, bio-CMOs, and biochemical companies — through a direct B2B sales motion driven by product inquiry forms, audit requests, and technical document requests on its corporate website, augmented by an authorized distributor network for global reach. Pricing is quote-based on grade, volume, and regulatory requirements, with long-term fixed pricing options offered to hedge against commodity fluctuation; the revenue model is one-time/shipment-based rather than subscription. BioSpectra employs 300+ staff across its Pennsylvania and Canada sites and has no external capital, no parent company, and no public listing.

BioSpectra's competitive positioning rests on three pillars: (i) exclusively North American manufacturing addressing pharmaceutical supply-chain security concerns, (ii) deep multi-jurisdictional regulatory documentation including DMF support, and (iii) capital-intensive, purpose-built cGMP capacity (notably the dedicated biological buffer facility opened in 2001) that creates long qualification cycles for new suppliers entering the customer base. The firm has expanded capacity continuously since 2011, most recently adding an 80,000 sq ft analytical services and automated packaging facility in 2024/2025, and has invested in sustainability credentials (EcoVadis, SBTi, CDP) consistent with global pharmaceutical procurement standards.

Short descriptiontext

BioSpectra is a privately-owned, Pennsylvania-based cGMP manufacturer of bulk fine chemicals, biological buffers, pharmaceutical excipients, and APIs, serving global bio-pharma companies, bio-CMOs, and biochemical companies exclusively from five North American facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBangor, United States
HQ citystring
Bangor
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cGMP fine chemicals, biological buffers manufacturing, pharmaceutical excipients, active pharmaceutical ingredients, custom pharmaceutical manufacturing
Industry3 codes
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAKAI
Raw Materials & Critical Reagents Supply Services (media, resins, single-use)
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Industrial Organic Chemicals2860
  • Chemicals & Allied Products2800
Product category
Pharmaceutical Fine Chemicals Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Fine Chemicals Sales
TypeOne Time License
Description

Revenue generated from the manufacture and sale of cGMP bulk biological buffers, cGMP buffer solutions, cGMP process fine chemicals, cGMP chlorinated amino acids, parenteral grade carbohydrates and carbohydrate polymers, and other novel and compendial excipients. Products are sold directly to bio pharma companies, bio-CMOs, and biochemical companies worldwide.

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom quotation based on product specifications, volume, and regulatory requirements
ModelUnit PricingBilling cadencePay-as-you-go
Notes

BioSpectra uses product inquiry forms for all pricing inquiries. Pricing varies by product grade, package size (100g to 50kg), and volume. Long-term fixed pricing available upon request.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1BioBuffer Solutions
Description

Brand supporting the need for upstream materials and buffer solutions for biopharmaceutical customers.

Core offering1 text field

BioSpectra manufactures and sells bulk cGMP fine chemicals, biological buffers, pharmaceutical excipients, and active pharmaceutical ingredients (APIs) exclusively in North America. The portfolio includes HEPES, MES, MOPS, Tris, Bis-Tris buffers, functional carbohydrates (D-Galactose, Trehalose, Dextran), large volume cGMP solutions, and APIs such as Potassium Bromide, all produced under ICH Q7 and IPEC GMP compliance for global bio-pharmaceutical customers.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BioSpectra is a privately-owned manufacturer of premium pharmaceutical ingredients and bulk cGMP fine chemicals, offering a comprehensive portfolio exclusively manufactured in North America. The product portfolio centers on cGMP biological buffers (HEPES, MES, MOPS, Tris, Bis-Tris), functional carbohydrates (D-Galactose, Trehalose, Dextran polymers), large volume cGMP solutions (NaOH, HCl, buffer solutions), active pharmaceutical ingredients (Potassium Bromide, Tris/Tromethamine), and cGMP process chemicals and excipients. The company operates under distinct quality tiers: ICH Q7 GMP manufactured APIs and excipients, IPEC GMP manufactured biotech products, and ISO registered products. Products are available in multiple grade variants including LBLE (Low Bioburden, Low Endotoxin), LEI (Low Elemental Impurities), and Ultra Low endotoxin options. Manufacturing is conducted at FDA-registered facilities in Bangor and Stroudsburg, PA, with additional facilities in Canada for Dextran products. The company also provides custom manufacturing services including spray dry technology.

Product and service2 records
1cGMP Fine Chemicals
CategorycGMP Fine Chemicals
Description

Bulk cGMP fine chemicals manufactured in North America, including process chemicals, chlorinated amino acids, and pharmaceutical intermediates compliant with ICH Q7 regulatory standards for bio-pharmaceutical manufacturers.

2cGMP Biological Buffers
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1BioSpectra Canada D.B.A. Dextran Products
Strategic tierCoreTypeOthers
Description

Scarborough, Ontario facility operating as BioSpectra Canada D.B.A. Dextran Products. This Canadian subsidiary produces, refines, and purifies dextran powders and related carbohydrate polymers before further processing at the FDA-registered Bangor, PA facility.

Recent move14 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is a global CDMO and supplier of cell culture media, buffers, excipients, and APIs for biopharma. It competes with BioSpectra in upstream materials (buffers, carbohydrates) and biological raw materials, with much larger scale and a global network but different core focus on contract manufacturing services.

TypeBroad incumbent
Description

Avantor is a global manufacturer and distributor of high-purity chemicals, excipients, and raw materials for biopharma, including buffers, process chemicals, and APIs. It is the largest direct competitor in BioSpectra's cGMP fine chemicals and biological buffer space, with a much broader catalog and global footprint but a less specialized North-American-only positioning.

TypeEmerging player
Description

Cayman Chemical supplies fine chemicals, biochemicals, and reagents for research and pharmaceutical applications, with growing cGMP capability. It overlaps with BioSpectra in biochemical buffers and fine chemicals, with a more research-focused base but expanding into pharma-grade offerings.

TypeDirect peer
Description

Polysciences manufactures specialty polymers, carbohydrates, and cGMP chemicals for pharmaceutical and life sciences applications, including dextran products comparable to BioSpectra's Canadian subsidiary offerings. It is a smaller, more specialized peer with comparable focus on high-purity carbohydrate polymers for life science use.

TypeBroad incumbent
Description

Thermo Fisher offers cGMP fine chemicals through its chemicals business and adjacent biopharma services. It is a broad incumbent that competes across BioSpectra's portfolio, with greater scale and cross-selling reach but less specialization in pure cGMP buffer and excipient manufacturing.

TypeDirect peer
Description

TCI Chemicals manufactures high-purity fine chemicals, reagents, and pharmaceutical-grade intermediates globally. It overlaps with BioSpectra's cGMP process chemicals and buffer offerings, with comparable quality grades and similar B2B customer base in pharma and life sciences.

7Excipient Solutions / Roquette
TypeDirect peer
Description

Roquette is a global leader in pharmaceutical excipients including carbohydrates, dextrans, and cyclodextrins — directly overlapping with BioSpectra's functional carbohydrate portfolio (D-Galactose, Trehalose, Dextran polymers). Both serve biopharma excipient buyers with compendial-grade materials, though Roquette has substantially larger scale and broader excipient breadth.

8Spectrum Chemical Mfg. Corp.
TypeDirect peer
Description

Spectrum Chemical is a direct peer in cGMP fine chemicals, buffers, and excipients for pharmaceutical and biopharmaceutical manufacturing. Both companies serve similar bio-pharma and CMO customers with overlapping product portfolios in biological buffers and process chemicals, though BioSpectra is more specialized in upstream/downstream biologics applications while Spectrum has broader lab-chemical reach.

9Merck KGaA (Life Science)
TypeBroad incumbent
Description

Through its Sigma-Aldrich brand, Merck KGaA supplies biological buffers (Tris, HEPES, MES, MOPS), excipients, and APIs globally under cGMP grades (SAFC). It competes directly with BioSpectra in buffer and process chemicals and has substantially deeper R&D, IP, and international distribution — though BioSpectra's exclusive North American manufacturing can be a differentiator for reshoring-focused buyers.

TypeBroad incumbent
Description

Honeywell's research chemicals business supplies high-purity buffers, solvents, and reagents under Fluka and related brands, including grades for pharma applications. It overlaps with BioSpectra's buffer and fine chemical offerings, with broader international reach but less emphasis on cGMP manufacturing for biological applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioSpectra

Pharmaceutical Fine Chemicals Manufacturingbiospectra.us

BioSpectra is a privately-owned, Pennsylvania-based cGMP manufacturer of bulk fine chemicals, biological buffers, pharmaceutical excipients, and APIs, serving global bio-pharma companies, bio-CMOs, and biochemical companies exclusively from five North American facilities.

What BioSpectra does

BioSpectra, Inc. is a privately-owned, US-domiciled (Pennsylvania) manufacturer of bulk cGMP fine chemicals, biological buffers, pharmaceutical excipients, functional carbohydrates, and APIs, with operations since 1995 across approximately 370,000 square feet of GMP-licensed space in five facilities in Pennsylvania and Ontario. Its core product categories are cGMP Fine Chemicals (process chemicals, chlorinated amino acids, large-volume solutions such as NaOH and guanidine HCl), cGMP Biological Buffers (HEPES, MES, MOPS, Tris, Bis-Tris and related zwitterionic buffers in biotech, excipient, LBLE, and ultra-low-endotoxin grades), Functional and Compendial Excipients (carbohydrates including D-Galactose, Trehalose and Dextran; parenteral-grade excipients), cGMP APIs (e.g., Potassium Bromide, Tromethamine/Tris), and Custom Manufacturing Services including spray-dry processing. Manufacturing runs under FDA registration, ICH Q7 for APIs, and IPEC GMP for excipients, with additional EU REACH registrations across multiple products and CEP/CPP country authorizations; product quality tiers include ICH Q7 GMP, IPEC GMP, and ISO registered QMS grades.

The company sells exclusively to enterprise pharmaceutical and biopharmaceutical buyers — leading bio-pharma companies, bio-CMOs, and biochemical companies — through a direct B2B sales motion driven by product inquiry forms, audit requests, and technical document requests on its corporate website, augmented by an authorized distributor network for global reach. Pricing is quote-based on grade, volume, and regulatory requirements, with long-term fixed pricing options offered to hedge against commodity fluctuation; the revenue model is one-time/shipment-based rather than subscription. BioSpectra employs 300+ staff across its Pennsylvania and Canada sites and has no external capital, no parent company, and no public listing.

BioSpectra's competitive positioning rests on three pillars: (i) exclusively North American manufacturing addressing pharmaceutical supply-chain security concerns, (ii) deep multi-jurisdictional regulatory documentation including DMF support, and (iii) capital-intensive, purpose-built cGMP capacity (notably the dedicated biological buffer facility opened in 2001) that creates long qualification cycles for new suppliers entering the customer base. The firm has expanded capacity continuously since 2011, most recently adding an 80,000 sq ft analytical services and automated packaging facility in 2024/2025, and has invested in sustainability credentials (EcoVadis, SBTi, CDP) consistent with global pharmaceutical procurement standards.

BioSpectra firmographics

Firmographics
Name
BioSpectra
Legal name
BioSpectra, Inc.
Website
https://biospectra.us
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
101–250 employees
Short description
BioSpectra is a privately-owned, Pennsylvania-based cGMP manufacturer of bulk fine chemicals, biological buffers, pharmaceutical excipients, and APIs, serving global bio-pharma companies, bio-CMOs, and biochemical companies exclusively from five North American facilities.
Ownership category
akta.pro rank

BioSpectra industry classification

Industry
Product category
Pharmaceutical Fine Chemicals Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Industrial Organic Chemicals (2860), Chemicals & Allied Products (2800)
akta.pro industry
PRIMARYHLAAAJAI
Bioprocess Consumables & Reagents (resins, membranes, media components, buffers)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAAAKAI
Raw Materials & Critical Reagents Supply Services (media, resins, single-use)
SECONDARYHLAGAGAI
Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • CGMP fine chemicals
  • Biological buffers manufacturing
  • Pharmaceutical excipients
  • Active pharmaceutical ingredients
  • Custom pharmaceutical manufacturing

Where BioSpectra is headquartered

Location

Headquarters

HQ city
Bangor
HQ country
United States
HQ region
North America

Offices5 records

Markets served

BioSpectra business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Fine Chemicals Sales: Revenue generated from the manufacture and sale of cGMP bulk biological buffers, cGMP buffer solutions, cGMP process fine chemicals, cGMP chlorinated amino acids, parenteral grade carbohydrates and carbohydrate polymers, and other novel and compendial excipients. Products are sold directly to bio pharma companies, bio-CMOs, and biochemical companies worldwide.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCustom quotation based on product specifications, volume, and regulatory requirements

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

BioSpectra product offering

Product offering

Core offering

BioSpectra manufactures and sells bulk cGMP fine chemicals, biological buffers, pharmaceutical excipients, and active pharmaceutical ingredients (APIs) exclusively in North America. The portfolio includes HEPES, MES, MOPS, Tris, Bis-Tris buffers, functional carbohydrates (D-Galactose, Trehalose, Dextran), large volume cGMP solutions, and APIs such as Potassium Bromide, all produced under ICH Q7 and IPEC GMP compliance for global bio-pharmaceutical customers.

Product overview

BioSpectra is a privately-owned manufacturer of premium pharmaceutical ingredients and bulk cGMP fine chemicals, offering a comprehensive portfolio exclusively manufactured in North America. The product portfolio centers on cGMP biological buffers (HEPES, MES, MOPS, Tris, Bis-Tris), functional carbohydrates (D-Galactose, Trehalose, Dextran polymers), large volume cGMP solutions (NaOH, HCl, buffer solutions), active pharmaceutical ingredients (Potassium Bromide, Tris/Tromethamine), and cGMP process chemicals and excipients. The company operates under distinct quality tiers: ICH Q7 GMP manufactured APIs and excipients, IPEC GMP manufactured biotech products, and ISO registered products. Products are available in multiple grade variants including LBLE (Low Bioburden, Low Endotoxin), LEI (Low Elemental Impurities), and Ultra Low endotoxin options. Manufacturing is conducted at FDA-registered facilities in Bangor and Stroudsburg, PA, with additional facilities in Canada for Dextran products. The company also provides custom manufacturing services including spray dry technology.

Differentiator

Problem solved

Functional benefit

Brands

  • BioBuffer Solutions: Brand supporting the need for upstream materials and buffer solutions for biopharmaceutical customers.

Products and services

  • cGMP Fine Chemicals Bulk cGMP fine chemicals manufactured in North America, including process chemicals, chlorinated amino acids, and pharmaceutical intermediates compliant with ICH Q7 regulatory standards for bio-pharmaceutical manufacturers.
  • cGMP Biological Buffers

Companies that use BioSpectra

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

BioSpectra technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

BioSpectra partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioSpectra Canada D.B.A. Dextran ProductscoreOthersScarborough, Ontario facility operating as BioSpectra Canada D.B.A. Dextran Products. This Canadian subsidiary produces, refines, and purifies dextran powders and related carbohydrate polymers before further processing at the FDA-registered Bangor, PA facility.

Scale indicators5 records

Recent moves14 records

Expansion highlights5 records

BioSpectra competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Lonza is a global CDMO and supplier of cell culture media, buffers, excipients, and APIs for biopharma. It competes with BioSpectra in upstream materials (buffers, carbohydrates) and biological raw materials, with much larger scale and a global network but different core focus on contract manufacturing services.
  • Avantor: Avantor is a global manufacturer and distributor of high-purity chemicals, excipients, and raw materials for biopharma, including buffers, process chemicals, and APIs. It is the largest direct competitor in BioSpectra's cGMP fine chemicals and biological buffer space, with a much broader catalog and global footprint but a less specialized North-American-only positioning.
  • Thermo Fisher Scientific (Patheon/CDMO and Chemicals): Thermo Fisher offers cGMP fine chemicals through its chemicals business and adjacent biopharma services. It is a broad incumbent that competes across BioSpectra's portfolio, with greater scale and cross-selling reach but less specialization in pure cGMP buffer and excipient manufacturing.
  • Merck KGaA (Life Science): Through its Sigma-Aldrich brand, Merck KGaA supplies biological buffers (Tris, HEPES, MES, MOPS), excipients, and APIs globally under cGMP grades (SAFC). It competes directly with BioSpectra in buffer and process chemicals and has substantially deeper R&D, IP, and international distribution — though BioSpectra's exclusive North American manufacturing can be a differentiator for reshoring-focused buyers.
  • Honeywell Research Chemicals (formerly Fluka): Honeywell's research chemicals business supplies high-purity buffers, solvents, and reagents under Fluka and related brands, including grades for pharma applications. It overlaps with BioSpectra's buffer and fine chemical offerings, with broader international reach but less emphasis on cGMP manufacturing for biological applications.

Emerging players

  • Cayman Chemical: Cayman Chemical supplies fine chemicals, biochemicals, and reagents for research and pharmaceutical applications, with growing cGMP capability. It overlaps with BioSpectra in biochemical buffers and fine chemicals, with a more research-focused base but expanding into pharma-grade offerings.

Direct peers

  • Polysciences Inc. Polysciences manufactures specialty polymers, carbohydrates, and cGMP chemicals for pharmaceutical and life sciences applications, including dextran products comparable to BioSpectra's Canadian subsidiary offerings. It is a smaller, more specialized peer with comparable focus on high-purity carbohydrate polymers for life science use.
  • TCI Chemicals: TCI Chemicals manufactures high-purity fine chemicals, reagents, and pharmaceutical-grade intermediates globally. It overlaps with BioSpectra's cGMP process chemicals and buffer offerings, with comparable quality grades and similar B2B customer base in pharma and life sciences.
  • Excipient Solutions / Roquette: Roquette is a global leader in pharmaceutical excipients including carbohydrates, dextrans, and cyclodextrins — directly overlapping with BioSpectra's functional carbohydrate portfolio (D-Galactose, Trehalose, Dextran polymers). Both serve biopharma excipient buyers with compendial-grade materials, though Roquette has substantially larger scale and broader excipient breadth.
  • Spectrum Chemical Mfg. Corp. Spectrum Chemical is a direct peer in cGMP fine chemicals, buffers, and excipients for pharmaceutical and biopharmaceutical manufacturing. Both companies serve similar bio-pharma and CMO customers with overlapping product portfolios in biological buffers and process chemicals, though BioSpectra is more specialized in upstream/downstream biologics applications while Spectrum has broader lab-chemical reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BioSpectra social profiles

Digital presence

BioSpectra compliance and trust

Trust signal

Compliance10 records

BioSpectra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioSpectra leadership team

Management profile

Number of profiles

Profiles1 record

BioSpectra subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

BioSpectra funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioSpectra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioSpectra

What does BioSpectra do?

BioSpectra manufactures and sells bulk cGMP fine chemicals, biological buffers, pharmaceutical excipients, and active pharmaceutical ingredients (APIs) exclusively in North America. The portfolio includes HEPES, MES, MOPS, Tris, Bis-Tris buffers, functional carbohydrates (D-Galactose, Trehalose, Dextran), large volume cGMP solutions, and APIs such as Potassium Bromide, all produced under ICH Q7 and IPEC GMP compliance for global bio-pharmaceutical customers.

Is BioSpectra a public or private company?

BioSpectra is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BioSpectra founded?

BioSpectra was founded in 1995. It employs 101 to 250 people.

Where is BioSpectra based?

BioSpectra is headquartered in Bangor, United States, in the North America region.

How does BioSpectra make money?

One revenue line is on record: pharmaceutical Fine Chemicals Sales.

Who are BioSpectra's main competitors?

Broad incumbents on record are Lonza Group, Avantor, Thermo Fisher Scientific (Patheon/CDMO and Chemicals), Merck KGaA (Life Science) and Honeywell Research Chemicals (formerly Fluka). Cayman Chemical is listed as an emerging player. Direct peers are Polysciences Inc., TCI Chemicals, Excipient Solutions / Roquette and Spectrum Chemical Mfg. Corp..

Does BioSpectra have an API?

No public API is recorded for BioSpectra.

What industry is BioSpectra in?

BioSpectra's product category is Pharmaceutical Fine Chemicals Manufacturing. Its primary akta.pro industry code is HLAAAJAI, Bioprocess Consumables & Reagents (resins, membranes, media components, buffers), with a secondary code of HLAAAKAI, Raw Materials & Critical Reagents Supply Services (media, resins, single-use). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals